Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroblastoma × Tissue Banks × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Ovarian Neoplasms 1 Neuroblastoma 1 Hepatoblastoma 1 Head and Neck Neoplasms 1 HER2 Positive Advanced Gastric Cancer 1 Basal Cell Carcinoma of the Head and Neck 1

Interventions

Cyclophosphamide 81 Etoposide 44 Temozolomide 37 Carboplatin 37 Filgrastim 36 Topotecan 35 Melphalan 35 Isotretinoin 35 Irinotecan 35 Vincristine 34 Doxorubicin 33 Granulocyte Colony-Stimulating Factor 25 Cisplatin 25 Peripheral Blood Stem Cell Transplantation 24 3-Iodobenzylguanidine 23 sargramostim 21 dinutuximab 21 Granulocyte-Macrophage Colony-Stimulating Factor 21 Radiotherapy 20 Busulfan 18 fludarabine 16 Magnetic Resonance Spectroscopy 16 naxitamab 13 aldesleukin 13 Thiotepa 13 Interleukin-2 13 fludarabine phosphate 12 humanized 3F8 anti-GD2 monoclonal antibody 11 etoposide phosphate 11 Stem Cell Transplantation 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Dana-Farber Cancer Institute

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡